US-EN
Select Country

One Product. Many modalities.

For 25 years, ISOVUE® has been the contrast agent of choice for thousands of health care professionals worldwide. Bracco has an unwavering commitment to producing safe and effective imaging products.

Since 1986, ISOVUE has been administered more than 300 million times by clinicians in 80 countries.1 ISOVUE offers desired flexibility by providing all the concentrations and fill sizes you will need, including the highest available concentration in the U.S., making it the contrast agent of choice for safe, effective imaging in a wide range of modalities, including computed tomography (CT), cardiac catheterization, peripheral vascular angiography and several other angiographic indications. And ISOVUE’s reputation for tolerability, flexibility, and safety are backed by thousands of studies worldwide. 

1.Data on file, Bracco Diagnostics Inc.

Ask your Bracco Representative about our Multidetector Computed Tomography (MDCT) Protocol Site, or Login Here.

 

Isovue image pack

ISOVUE® Imaging Bulk Package

ISOVUE® Imaging Bulk
Package offers
multi-dosing,
efficiency in 200 mL
and 500 mL volumes.

Read more

Modalities

ISOVUE® offers safe,
effective imaging
for a wide range
of modalities, including
CT, cardiac cath,
peripheral vascular
and several other angiographic
indications.

Read more

Registration

Register to receive
the latest news
and updates
on ISOVUE.

Read more

Find Your Rep

Enter your ZIP code in the box below:

INDICATIONS AND USAGE:
ISOVUE (iopamidol injection) is indicated for angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography), and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging.

IMPORTANT SAFETY INFORMATION:
ISOVUE® (iopamidol injection) IS NOT FOR INTRATHECAL USE. 
Iopamidol injection is available as ISOVUE-M®for intrathecal administration.

Nonionic iodinated contrast media inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events. Caution must be exercised in patients with severely impaired renal function, those with combined renal and hepatic disease, or anuria, particularly when larger and repeat doses are administered. Radiopaque diagnostic contrast agents are potentially hazardous in patients with multiple myeloma or other paraproteinemia, particularly in those with therapeutically resistant anuria. Caution should be exercised in hydrating patients with underlying conditions that may be worsened by fluid overload, such as congestive heart failure. Diabetic nephropathy may predispose to acute renal impairment following intravascular contrast media administration. Acute renal impairment following contrast media administration may precipitate lactic acidosis in patients who are taking biguanides. Preparatory dehydration is dangerous and may contribute to acute renal failure in patients with advanced vascular disease, diabetic patients, and in susceptible nondiabetic patients (often elderly with preexisting renal disease). Patients should be well hydrated prior to and following iopamidol administration. The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions, should always be considered. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies).The need for myelographic examination should be carefully evaluated. Iopamidol should be administered with caution in patients with increased intracranial pressure or suspicion of intracranial tumor, abscess or hematoma, those with a history of convulsive disorder, severe cardiovascular disease, chronic alcoholism, or multiple sclerosis, and elderly patients. Particular attention must be given to state of hydration, concentration of medium, dose, and technique used in these patients.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please download full Prescribing Information by clicking here.

ISOVUE®, ISOVUE-M® and ISOVUE Multipack® are currently manufactured for Bracco Diagnostics Inc. at two locations:
BIPSO GmbH, Singen, Germany
Patheon Italia SpA, Ferentino, Italy

Isovue is a registered trademark of Bracco Diagnostics Inc.